ClinicalTrials.gg
CompletedNCT04008732FM58Updated Jul 5, 2019

Evaluating MED2005 & Nitrostat Bioavailability

A Phase 1 interventional study of MED2005 and Nitrostat 0.6Mg Sublingual Tablet in Erectile Dysfunction, sponsored by Futura Medical Developments Ltd.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by Futura Medical Developments Ltd. · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was Apr 2018, 8 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Erectile Dysfunction with a site in United Kingdom — 3 open to participants now, 4 under way, none of them phase 3. Erectile Dysfunction · United Kingdom.

Enrollment
18th of 23
40 · median 260
Started
2017
the only one that year
Phase 1
2 of 25
none open now
Registered
19th of 25
by date
Lead sponsor
2 of 25
Futura Medical Developments Ltd.

Among the 25 studies in Erectile Dysfunction with a site in United Kingdom, this one is the 18th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2017, is one of 2 in phase 1, and was the 19th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

3 of the 25 studies in Erectile Dysfunction with a site in United Kingdom are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Erectile Dysfunction with a site in United Kingdom, or all of them as a file.
02

Study summary

Futura Medical Developments Ltd (FMD) are developing a gel formulation of GTN (MED2005) as a topical treatment for ED delivered using DermaSys®, a versatile and bespoke technology. Treatment requires the application of a small quantity of gel (approx 300 mg), containing a fixed dose of GTN, to the glans of the penis. Pharmacokinetic studies in healthy volunteers indicate rapid absorption of the drug and low systemic exposure, reducing the risk of adverse events (such as headache) commonly associated with GTN therapy.

The purpose of this study is to demonstrate similar or lower bioavailability of GTN from MED2005 (test IMP) with that from Nitrostat (reference IMP).

The study will be conducted in two parts (Part 1 and 2). Part 1 will be conducted in 30 subjects and Part 2 will be conducted in 10 subjects. Part 1 will compose of a pre-study screen, followed by six treatment periods and a post-study follow-up.

Part 2 will compose of a pre-study screen, followed by two treatment periods and a post-study follow-up. Subjects can only participate in either Part 1 or 2 of the study (not both).

Read the detailed description

GTN is a well-established vasodilatory therapeutic agent with a long, documented history of use and comprehensive safety profile. In Europe, licensed indications for GTN include the treatment and prophylaxis of angina pectoris and the relief of pain associated with chronic anal fissure. Other indications for prescription only parenteral products include use during cardiac surgery and for emergency reduction of blood pressure.

GTN's vasodilatory action is thought to result from the release of nitric oxide (NO) in vascular smooth muscle. NO stimulates guanylate cyclase, the enzyme responsible for production of cGMP, whose action is to lower intracellular calcium resulting in smooth muscle relaxation and vasodilation.

In the case of erectile dysfunction, GTN works locally by penetrating the glans/penile skin and directly targeting penile blood vessels. Nitrates appear to have a direct, local effect on penile haemodynamics. The most likely mechanism for the erectile effect of nitrates involves nitrate induced dilation of the cavernous and helicine arteries, thereby increasing blood flow to the lacunar spaces, coupled with nitrate-induced relaxation of trabecular smooth muscle.

Nitroglycerin (Nitrostat) is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle. Although venous effects predominate, nitroglycerin produces, in a dose-related manner, dilation of both arterial and venous beds. Dilation of postcapillary vessels, including large veins, promotes peripheral pooling of blood, decreases venous return to the heart, and reduces left ventricular end-diastolic pressure (preload). Nitroglycerin also produces arteriolar relaxation, thereby reducing peripheral vascular resistance and arterial pressure (afterload), and dilates large epicardial coronary arteries; however, the extent to which this latter effect contributes to the relief of exertional angina is unclear.

Nitroglycerin forms free radical nitric oxide (NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects between 18 and 50 years of age, inclusive (at screening).
  2. A of 18.5-30 kg/m2 (inclusive).
  3. No clinical significant abnormal serum biochemistry, haematology and urine examination values as defined by the Investigator.
  4. A negative urinary drugs of abuse screen. A positive alcohol test may be repeated on admission at the discretion of the Investigator.
  5. Negative and and C results.
  6. No abnormalities in 12-lead as defined by the Investigator.
  7. No clinically significant deviation outside the normal ranges for blood pressure and heart rate measurements as defined by the Investigator (please refer to appendix 1 for normal ranges).
  8. Subjects (unless anatomically sterile (documented evidence) or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) and sexual partners must use 2 effective methods during the trial and for 3 months after the last dose, for example:

    • Oral contraceptive + condom.
    • Intra-uterine device (IUD) + condom.
    • Diaphragm with spermicide + condom.
  9. Subjects must be available to complete all periods of the study and the follow-up visit.
  10. Subjects must satisfy the PI / designee about their fitness to participate in the study.
  11. Subjects must be able to read and understand the form and must provide written informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. A history of gastrointestinal disorder likely to influence IMP absorption (Part 1 only).
  2. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 28 days (or 5 half-lives (whichever is longer) prior to the first dose of IMP, unless in the opinion of the Investigator and Sponsor's Responsible Physician the medication will not interfere with the study procedures or compose subject safety.
  3. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
  4. A clinically significant history of drug or alcohol abuse within 2 years before the first dose of IMP.
  5. A clinically significant history of previous allergy/sensitivity to GTN, other nitrates and/or any of the in either the test of reference products.
  6. Recent history of using PDE5 inhibitors or alkyl nitrates (e.g. poppers).
  7. A history of frequent tension headaches or vascular headaches or migraine.
  8. A history of increased intra-cranial pressure or spinal cord injury.
  9. A history of severe psychological disorders.
  10. A presence of scarring/piercings/tattoos at the site of MED2005 administration (penis) (or any other features that the Investigator considers may influence IMP absorption).
  11. Subjects (if uncircumcised) who are not able to retract foreskin of penis easily without any discomfort.
  12. Any obvious sensitivity/local tolerability issues at the site of medication application.
  13. Inability to communicate well with the investigator (i.e. language problems, poor mental development or impaired cerebral function).
  14. Participation in a New Chemical Entity or marketed drug clinical study within the previous 3 months or, five half-lives of study drug, whichever is the longer period. (NB. the three month between trials is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
  15. Subjects who smoke (or ex-smokers) who have smoked or used nicotine-containing products (including snuff, chewing tobacco, cigars, pipes or nicotine replacement products) within four months prior to first dose.
  16. Donation or receipt of ≥ 450 mL of blood within 3 months before the first dose of IMP.
  17. Donation of sperm from the first dose and for at least 3 months after the last dose of IMP.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    MED2005 (0.6 mg)

    MED2005 (0.2% GTN) gel to be used topically in Part 1 of the study

    Drug: MED2005 · Drug: Nitrostat 0.6Mg Sublingual Tablet

  • Experimental
    MED2005 (1.2 mg)

    MED2005 (0.4% GTN) gel to be used topically in Part 1 of the study

    Drug: MED2005 · Drug: Nitrostat 0.6Mg Sublingual Tablet

  • Experimental
    MED2005 (1.8 mg)

    MED2005 (0.6% GTN) gel to be used topically in Part 1 of the study

    Drug: MED2005 · Drug: Nitrostat 0.6Mg Sublingual Tablet

  • Active comparator
    Nitrostat (1.8 mg) - Treatment Period 1

    3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods

    Drug: MED2005 · Drug: Nitrostat 0.6Mg Sublingual Tablet

  • Active comparator
    Nitrostat (1.8 mg) - Treatment Period 2

    3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods

    Drug: MED2005 · Drug: Nitrostat 0.6Mg Sublingual Tablet

  • Experimental
    MED2005 (2.4 mg)- Part 1

    MED2005 (0.8% GTN) gel to be used topically in Part 1 of the study

    Drug: MED2005 · Drug: Nitrostat 0.6Mg Sublingual Tablet

  • Active comparator
    Intravenous (I.V.) dose of GTN (0.3 mg)

    GTN solution for infusion (1 mg/ml) to be used intravenously in Part 2 of the study

    Drug: Nitro Pohl

  • Experimental
    MED2005 (2.4 mg)- Part 2

    MED2005 (0.8% GTN) gel to be used topically in Part 2 of the study

    Drug: Nitro Pohl

Interventions

  • (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.

    Also known as: glyceryl trinitrate

  • Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.

    Also known as: Nitroglycerin 0.6 mg

  • to be dosed intravenously in Part 2 of the study

    Also known as: Nitroglycerin

06

What researchers measure

Primary outcomes

  1. To demonstrate similar or lower bioavailability of GTN when administered as a gel via MED2005 compared to Nitrostat (which will administrated as a sublingual tablet) in terms of AUC0-t (Part 1)

    The primary objective of this human pharmacology study is to demonstrate similar or lower bioavailability of GTN

    Time frame: 22 days

  2. To demonstrate similar or lower bioavailability of GTN when administered as a gel via MED2005 compared to Nitrostat (which will administrated as a sublingual tablet) in terms of AUC0-inf (Part1)

    The primary objective of this human pharmacology study is to demonstrate similar or lower bioavailability of GTN

    Time frame: 22 days

  3. To demonstrate similar or lower bioavailability of GTN when administered as a gel via MED2005 compared to Nitrostat (which will administrated as a sublingual tablet) in terms of Cmax (part1)

    The primary objective of this human pharmacology study is to demonstrate similar or lower bioavailability of GTN

    Time frame: 22 days

Secondary outcomes

  1. The pharmacokinetics of GTN metabolite 1,2-GDN will be evaluated following the administration of MED2005 compared with Nitrostat (Part 1).

    The percentage of drug metabolites in the bloodstream following administration of MED2005 (test formulation) with Nitrostat (reference) (part 1) will be compared and evaluated.

    Time frame: 22 days

  2. Adverse events (AEs) coded using Medical Dictionary for Regulatory Activities (MedDRA) version 20.0 or higher

    The incidence of treatment-emergent AEs (TEAE) will be summarised by organ system, preferred term, severity and relationship to study drug. AEs will be identified via abnormal vital signs, abnormal 12-lead ECG parameters, and/or abnormal laboratory safety data

    Time frame: 46 days

  3. GTN absorption (to quantify the amount of GTN remaining on the glans penis post application)

    To quantify the amount of GTN remaining on the glans penis post application of MED2005 (Part 2).

    Time frame: 10 days

  4. GTN absorption (to quantify a figure of 100% GTN being absorbed)

    I.V. dosing to quantify a figure of 100% GTN being absorbed (Part 2).

    Time frame: 10 days

  5. The pharmacokinetics of GTN metabolite1,3-GDN will be evaluated following the administration of MED2005 compared with Nitrostat (Part 1).

    the percentage of drug metabolites in the bloodstream following administration of MED2005 (test formulation) with Nitrostat (reference) (part 1) will be compared and evaluated.

    Time frame: 22 days

07

Study locations

1 site
  • Simbec Research Limited
    Merthyr Tydfil, Wales CF48 4DR, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Apr 2018, 5 months.

Of 18 phase 1 interventional studies under Erectile Dysfunction, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 19. This study's 5 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2018
First posted
Jul 5, 2019
StartActual
Nov 15, 2017
Primary completionActual
Apr 16, 2018
CompletionActual
Apr 16, 2018
Last update
Jul 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04008732
Lead sponsor
Futura Medical Developments Ltd.
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Nov 15, 2017
Primary completion
Apr 16, 2018
Completion
Apr 16, 2018
Last update
Jul 5, 2019

Study contacts

Samuel Israel, Israel
principal investigator · Simbec Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion